<DOC>
	<DOCNO>NCT01004081</DOCNO>
	<brief_summary>The purpose study ass efficacy , safety tolerability 2 dosing regimen BIIB021 combination exemestane woman whose HR+ breast cancer progress follow treatment nonsteroidal aromatase inhibitor ( AI ) .</brief_summary>
	<brief_title>Hormone Receptor Positive Metastatic Breast Cancer ( HR+ mBC ) BIIB021 Plus Aromasin Schedule Finding</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Exemestane</mesh_term>
	<criteria>Age 18 year age Must histologically cytologically confirm estrogen receptor positive progesterone receptorpositive , incurable , locally advanced , metastatic breast cancer . Must disease progression treatment nonsteroidal AI locally advance metastatic disease , relapse treatment within 12 month discontinuation treatment adjuvant setting . Must postmenopausal female . Must measurable evaluable disease . Measurable disease define &gt; =1 lesion diameter &gt; =10 mm Evaluable disease define bone lesion evaluable plain X ray , CT scan , MRI . Lesions identify radionuclide bone scan allow . One prior chemotherapy regimen advance mBC allow . Prior radiotherapy allow . Must able swallow retain oral medication . ECOG performance status &lt; =2 Required laboratory value Plasma cortisol adrenocorticotropic hormone ( ACTH ) level suggestive adrenal insufficiency unless replacement therapy know adrenal insufficiency . HER2 overexpressing tumor . History central nervous system ( CNS ) metastasis . Previous treatment exemestane treatment Hsp90 inhibitor . Use proton pump inhibitor . Known history positive test result hepatitis B C HIV . History gastrectomy major surgery small intestine .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2011</verification_date>
	<keyword>Cancer Breast</keyword>
	<keyword>Cancer Breast</keyword>
</DOC>